Found 10 matching trials
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy PHASE2 The purpose of this study is to evaluate the efficacy and safety of CHF6001...
Show More Location
Site 032020 - Instituto Especialidades de la Salud Rosario - Clinica del Torax
Learn More & Join Trial
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD PHASE2 The purpose of this study is to evaluate the dose-response relationship of ...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics PHASE2 The study is designed to look at the safety, tolerability and efficacy of 2...
Show More Location
Hammersmith Medicines Research
Learn More & Join Trial
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 PHASE1 A phase I randomised, double-blind, placebo-controlled study of single and ...
Show More Location
Quotient Clinical
Learn More & Join Trial
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) PHASE3 The purpose of the study is to evaluate the efficacy and safety of two dose...
Show More Location
Chiesi Clinical Trial - Site 840402
Learn More & Join Trial
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD PHASE2 Effect of CHF 6001 on biomarkers of inflammation in induced sputum and in b...
Show More Location
Medicines Evaluation Unit Ltd
Learn More & Join Trial
Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV) PHASE1 This study is designed to investigate the safety, tolerability and pharmaco...
Show More Location
Quotient Clinical
Learn More & Join Trial
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) PHASE3 The purpose of this study is to evaluate the efficacy and the safety of two...
Show More Location
Chiesi Clinical Trial - Site 840635
Learn More & Join Trial
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients PHASE2 Phase IIa study in COPD patients aimed to evaluate the safety, tolerability...
Show More Learn More & Join Trial
Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 PHASE1 To evaluate systemic pharmacokinetics of CHF6001 following concomitant admi...
Show More Learn More & Join Trial